Faculty of Pharmacy, University of Indonesia, Depok, Indonesia.
Department of Neurology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
Curr Diabetes Rev. 2023;19(2):e190522205028. doi: 10.2174/1573399818666220519140903.
This study aims to determine the prevalence of Type 2 Diabetes Mellitus (T2DM) in primary Brain Tumor (BT) subjects and assess the relationship between serum mutant p53 serum and HbA1c and insulin.
T2DM is known to increase the risk of various types of cancer, which are thought to be caused by hyperglycemia, hyperinsulinemia, and inflammation. A cohort study that looked at more than 500,000 subjects with DM over 11 years showed an increased risk of different types of cancer, including brain tumors. However, several recent studies have shown the opposite. One of the important pathways in the pathogenesis of brain tumors is the p53 pathway, in which mutations in the TP53 gene can cause brain cell growth abnormalities.
The first stage involved taking subject data for the period January 2017-November 2020 from the medical records of the RSUPN Dr. Cipto Mangunkusumo Hospital Indonesia to assess the prevalence of T2DM in BT subjects. The second stage was an observational study with a crosssectional design that collected primary data on subjects (n=86) to assess the relationship between serum mutant p53 serum and HbA1c and insulin.
The analysis of serum mutant p53 serum and insulin was made using the ELISA method, while measurement of HbA1c was made using the boronate affinity method.
The results show the prevalence of T2DM in BT subjects at Dr. Cipto Mangunkusumo Hospital Indonesia was relatively low (9%). Serum mutant p53 levels in T2DM (1.53 ng/mL ± 0.60) were significantly higher than in BT+T2DM and BT (P < 0.001). The HbA1c value was significantly lower in BT (5.15% ± 0.44) compared to BT+T2DM and T2DM (P < 0.001), while T2DM insulin levels (39.54 IU/mL ± 19.1) were significantly higher than BT+T2DM and BT (P < 0.001). There was no correlation between serum mutant p53 levels and HbA1c and insulin in the three groups.
The study concludes that the prevalence of BT with T2DM is relatively low (9%) and that serum levels of mutant p53 in T2DM subjects are higher than in subjects with BT, but there is no correlation between serum mutant p53 levels and HbA1c and insulin values. Further research needs to be conducted by analyzing p53 mutants from other specimens, such as brain tumor tissue.
本研究旨在确定原发性脑肿瘤（BT）患者中 2 型糖尿病（T2DM）的患病率，并评估血清突变型 p53 与 HbA1c 和胰岛素之间的关系。
众所周知，T2DM 会增加各种癌症的风险，这被认为是由高血糖、高胰岛素血症和炎症引起的。一项对超过 500,000 名患有 11 年以上 DM 的患者进行的队列研究表明，不同类型的癌症（包括脑肿瘤）的风险增加。然而，最近的几项研究结果却相反。脑肿瘤发病机制中的一个重要途径是 p53 途径，其中 TP53 基因突变可导致脑细胞生长异常。
第一阶段从印度尼西亚 Cipto Mangunkusumo 医院的病历中获取 2017 年 1 月至 2020 年 11 月期间的受试者数据，以评估 BT 受试者中 T2DM 的患病率。第二阶段是一项观察性研究，采用横断面设计，收集了 86 名受试者的原始数据，以评估血清突变型 p53 与 HbA1c 和胰岛素之间的关系。
使用 ELISA 法分析血清突变型 p53 血清和胰岛素，使用硼酸亲和法测量 HbA1c。
结果显示，印度尼西亚 Cipto Mangunkusumo 医院 BT 患者中 T2DM 的患病率相对较低（9%）。T2DM 患者血清突变型 p53 水平（1.53ng/mL±0.60）明显高于 BT+T2DM 和 BT 患者（P<0.001）。与 BT+T2DM 和 T2DM 患者相比，BT 患者的 HbA1c 值明显较低（5.15%±0.44）（P<0.001），而 T2DM 胰岛素水平（39.54IU/mL±19.1）明显高于 BT+T2DM 和 BT 患者（P<0.001）。三组中，血清突变型 p53 水平与 HbA1c 和胰岛素之间无相关性。
本研究表明，BT 合并 T2DM 的患病率相对较低（9%），T2DM 患者血清突变型 p53 水平高于 BT 患者，但血清突变型 p53 水平与 HbA1c 和胰岛素值之间无相关性。需要进一步研究，通过分析来自其他标本（如脑肿瘤组织）的 p53 突变体来进行。
